{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:47:38Z","timestamp":1794682058365,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Irish Department of Agriculture, Food and the Marine and Health Research Board"},{"DOI":"10.13039\/100008303","name":"Department for Employment and Learning, Northern Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Genome-wide and clinical studies have linked the 677C\u2192T polymorphism in the gene encoding methylenetetrahydrofolate reductase (MTHFR) with hypertension, whilst limited evidence shows that intervention with riboflavin (i.e. the MTHFR co-factor) can lower blood pressure (BP) in hypertensive patients with the variant <jats:italic>MTHFR<\/jats:italic> 677TT genotype. We investigated the impact of this common polymorphism on BP throughout adulthood and hypothesised that riboflavin status would modulate the genetic risk of hypertension.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Observational data on 6076 adults of 18\u2013102\u2009years were drawn from the Joint Irish Nutrigenomics Organisation project, comprising the Trinity-Ulster Department of Agriculture (TUDA; volunteer sample) and the National Adult Nutrition Survey (NANS; population-based sample) cohorts. Participants were recruited from the Republic of Ireland and Northern Ireland (UK) in 2008\u20132012 using standardised methods.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The variant <jats:italic>MTHFR<\/jats:italic> 677TT genotype was identified in 12% of adults. From 18 to 70\u2009years, this genotype was associated with an increased risk of hypertension (i.e. systolic BP \u2265\u2009140 and\/or a diastolic BP \u2265\u200990\u2009mmHg): odds ratio (OR) 1.42, 95% confidence interval (CI) 1.07 to 1.90; <jats:italic>P<\/jats:italic>\u2009=\u20090.016, after adjustment for antihypertensive drug use and other significant factors, namely, age, male sex, BMI, alcohol and total cholesterol. Low or deficient biomarker status of riboflavin (observed in 30.2% and 30.0% of participants, respectively) exacerbated the genetic risk of hypertension, with a 3-fold increased risk for the TT genotype in combination with deficient riboflavin status (OR 3.00, 95% CI, 1.34\u20136.68; <jats:italic>P<\/jats:italic>\u2009=\u20090.007) relative to the CC genotype combined with normal riboflavin status. Up to 65\u2009years, we observed poorer BP control rates on antihypertensive treatment in participants with the TT genotype (30%) compared to those without this variant, CT (37%) and CC (45%) genotypes (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.027).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The <jats:italic>MTHFR<\/jats:italic> 677TT genotype is associated with higher BP independently of homocysteine and predisposes adults to an increased risk of hypertension and poorer BP control with antihypertensive treatment, whilst better riboflavin status is associated with a reduced genetic risk. Riboflavin intervention may thus offer a personalised approach to prevent the onset of hypertension in adults with the TT genotype; however, this requires confirmation in a randomised trial in non-hypertensive adults.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12916-020-01780-x","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T02:02:17Z","timestamp":1605060137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Impact of the common MTHFR 677C\u2192T polymorphism on blood pressure in adulthood and role of riboflavin in modifying the genetic risk of hypertension: evidence from the JINGO project"],"prefix":"10.1186","volume":"18","author":[{"given":"Mary","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine F.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conal","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Horigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McCarroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"O\u2019Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Gibney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breige A.","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-6457","authenticated-orcid":false,"given":"Helene","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"1780_CR1","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"1780_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","volume":"389","author":"NCD Risk Factor Collaboration","year":"2017","unstructured":"NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19\u00b71 million participants. Lancet. 2017;389:37\u201355.","journal-title":"Lancet."},{"key":"1780_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jama.2013.184182","volume":"310","author":"CK Chow","year":"2013","unstructured":"Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959\u201368.","journal-title":"JAMA."},{"key":"1780_CR4","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"Prospective Studies Collaboration","year":"2002","unstructured":"Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903\u201313.","journal-title":"Lancet."},{"key":"1780_CR5","first-page":"e38","volume":"133","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics\u20142016 update. Circulation. 2015;133:e38\u201348.","journal-title":"Circulation."},{"key":"1780_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/ng.361","volume":"41","author":"C Newton-Cheh","year":"2009","unstructured":"Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666\u201376.","journal-title":"Nat Genet"},{"key":"1780_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature10405","volume":"478","author":"GB Ehret","year":"2011","unstructured":"Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103\u20139.","journal-title":"Nature."},{"key":"1780_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087497","volume":"9","author":"B Yang","year":"2014","unstructured":"Yang B, Fan S, Zhi X, Li Y, Liu Y, Wang D, et al. Associations of MTHFR gene polymorphisms with hypertension and hypertension in pregnancy: a meta-analysis from 114 studies with 15411 cases and 21970 controls. PLoS One. 2014;9:e87497.","journal-title":"PLoS One"},{"key":"1780_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3892\/br.2014.302","volume":"2","author":"KM Yang","year":"2014","unstructured":"Yang KM, Jia J, Mao LN, Men C, Tang KT, Li YY, et al. Methylenetetrahydrofolate reductase C677T gene polymorphism and essential hypertension: a meta-analysis of 10,415 subjects. Biomed Reports. 2014;2:699\u2013708.","journal-title":"Biomed Reports"},{"key":"1780_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/jhh.2011.11","volume":"26","author":"WQ Niu","year":"2012","unstructured":"Niu WQ, You YG, Qi Y. Strong association of methylenetetrahydrofolate reductase gene C677T polymorphism with hypertension and hypertension-in-pregnancy in Chinese: a meta-analysis. J Hum Hypertens. 2012;26:259\u201367.","journal-title":"J Hum Hypertens"},{"key":"1780_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/jmg.40.8.619","volume":"40","author":"B Wilcken","year":"2003","unstructured":"Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Renlund M, et al. Geographical and ethnic variation of the 677C\u2192T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas worldwide. J Med Genet. 2003;40:619\u201325.","journal-title":"J Med Genet"},{"key":"1780_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0140-6736(05)70152-5","volume":"365","author":"JP Casas","year":"2005","unstructured":"Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365:224\u201332.","journal-title":"Lancet."},{"key":"1780_CR13","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S0140-6736(11)60872-6","volume":"378","author":"MV Holmes","year":"2011","unstructured":"Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet. 2011;378:584\u201394.","journal-title":"Lancet."},{"key":"1780_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mam.2016.10.002","volume":"53","author":"H McNulty","year":"2017","unstructured":"McNulty H, Strain JJ, Hughes CF, Ward M. Riboflavin, MTHFR genotype and blood pressure: a personalized approach to prevention and treatment of hypertension. Mol Asp Med. 2017;53:2\u20139.","journal-title":"Mol Asp Med"},{"key":"1780_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/HJH.0b013e328334c126","volume":"28","author":"G Horigan","year":"2010","unstructured":"Horigan G, McNulty H, Ward M, Strain J, Purvis J, Scott JM. Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C\u2192T polymorphism in MTHFR. J Hypertens. 2010;28:478\u201386.","journal-title":"J Hypertens"},{"key":"1780_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3945\/ajcn.111.026245","volume":"95","author":"CP Wilson","year":"2012","unstructured":"Wilson CP, Ward M, McNulty H, Strain JJ, Trouton TG, Horigan G, et al. Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up. Am J Clin Nutr. 2012;95:766\u201372.","journal-title":"Am J Clin Nutr"},{"key":"1780_CR17","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1161\/HYPERTENSIONAHA.111.01047","volume":"61","author":"CP Wilson","year":"2013","unstructured":"Wilson CP, McNulty H, Ward M, Strain JJ, Trouton TG, Hoeft BA, et al. Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial. Hypertension. 2013;61:1302\u20138.","journal-title":"Hypertension."},{"key":"1780_CR18","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1210\/jc.2018-01791","volume":"104","author":"KM Porter","year":"2019","unstructured":"Porter KM, Ward M, Hughes CF, O\u2019Kane M, Hoey L, McCann A, et al. Hyperglycemia and metformin use are associated with B-vitamin deficiency and cognitive dysfunction in older adults. J Clin Endocrinol Metab. 2019;104:4837\u201347.","journal-title":"J Clin Endocrinol Metab"},{"key":"1780_CR19","unstructured":"Irish Universities Nutrition Alliance. National Adult Nutrition Survey: summary report. 2011. www.iuna.net\/surveyreports. Accessed May 2020."},{"key":"1780_CR20","volume-title":"Hypertension in adults: diagnosis and management. National Institute for Health and Care Excellence (NICE Clinical Guideline CG127)","author":"NICE","year":"2011","unstructured":"NICE. Hypertension in adults: diagnosis and management. National Institute for Health and Care Excellence (NICE Clinical Guideline CG127). London: NICE; 2011."},{"key":"1780_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003423","volume":"3","author":"M Joffres","year":"2013","unstructured":"Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013;3:e003423.","journal-title":"BMJ Open"},{"key":"1780_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamacardio.2019.5306","volume":"5","author":"H Ji","year":"2020","unstructured":"Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN, et al. Sex differences in blood pressure trajectories over the life course. JAMA Cardiol. 2020;5:255\u201362.","journal-title":"JAMA Cardiol"},{"key":"1780_CR23","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/S0140-6736(14)60688-7","volume":"383","author":"E Falaschetti","year":"2014","unstructured":"Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet. 2014;383:1912\u20139.","journal-title":"Lancet."},{"key":"1780_CR24","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1097\/HJH.0b013e32832a9ba3","volume":"27","author":"TA Gaziano","year":"2009","unstructured":"Gaziano TA, Bitton A, Anand S, Weinstein MC. The global cost of nonoptimal blood pressure. J Hypertens. 2009;27:1472\u20137.","journal-title":"J Hypertens"},{"key":"1780_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1017\/S0029665119000661","volume":"78","author":"H McNulty","year":"2019","unstructured":"McNulty H, Ward M, Hoey L, Hughes CF, Pentieva K. Addressing optimal folate and related B-vitamin status through the lifecycle: health impacts and challenges. Proc Nutr Soc. 2019;78:449\u201362.","journal-title":"Proc Nutr Soc"},{"key":"1780_CR26","first-page":"e04919","volume":"15","author":"EFSA Panel on Dietetic Products Nutrition and Allergies (NDA)","year":"2017","unstructured":"EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Dietary reference values for riboflavin. EFSA J. 2017;15:e04919.","journal-title":"EFSA J"},{"key":"1780_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2020.0109","volume":"5","author":"L Corlin","year":"2020","unstructured":"Corlin L, Short MI, Vasan RS, Xanthakis V. Association of the duration of ideal cardiovascular health through adulthood with cardiometabolic outcomes and mortality in the Framingham Offspring study. JAMA Cardiol. 2020;5:1\u20138.","journal-title":"JAMA Cardiol"},{"key":"1780_CR28","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2016.7050","volume":"315","author":"JD Williamson","year":"2016","unstructured":"Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 years: a randomized clinical trial. JAMA. 2016;315:2673\u201382.","journal-title":"JAMA."},{"key":"1780_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet."},{"key":"1780_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/jamacardio.2019.6192","volume":"5","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Juraschek SP, Solomon SD. Assessment of long-term benefit of intensive blood pressure control on residual life span: secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol. 2020;5:576\u201381.","journal-title":"JAMA Cardiol"},{"key":"1780_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002410","volume":"14","author":"S Basu","year":"2017","unstructured":"Basu S, Sussman JB, Rigdon J, Steimle L, Denton BT, Hayward RA. Benefit and harm of intensive blood pressure treatment: derivation and validation of risk models using data from the SPRINT and ACCORD trials. PLoS Med. 2017;14:e1002410.","journal-title":"PLoS Med"},{"key":"1780_CR32","doi-asserted-by":"crossref","unstructured":"Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435\u201343. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/339317\/SACN_Dietary_Reference_Values_for_Energy.pdf.","DOI":"10.1016\/S0140-6736(15)00805-3"},{"key":"1780_CR33","unstructured":"Public Health England. National Diet and Nutrition Survey Results from Years 1, 2, 3 and 4 (combined) of the Rolling Programme (2008\/2009\u20132011\/2012). 2014."},{"key":"1780_CR34","doi-asserted-by":"crossref","unstructured":"McNulty H, Strain JJ, Hughes CF, Pentieva K, Ward M. Evidence of a role for one-carbon metabolism in blood pressure: can B vitamin intervention address the genetic risk of hypertension owing to a common folate polymorphism? Curr Dev Nutr. 2020;4:nzz102.","DOI":"10.1093\/cdn\/nzz102"},{"key":"1780_CR35","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.106.612325","volume":"114","author":"C Antoniades","year":"2006","unstructured":"Antoniades C, Shirodaria C, Warrick N, Cai S, De Bono J, Lee J, et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and eNOS coupling. Circulation. 2006;114:1193\u2013201.","journal-title":"Circulation."},{"key":"1780_CR36","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1161\/CIRCULATIONAHA.108.808675","volume":"119","author":"C Antoniades","year":"2009","unstructured":"Antoniades C, Shirodaria C, Leeson P, Baarholm OA, Van-Assche T, Cunnington C, et al. MTHFR 677 C>T polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation. 2009;119:2507\u201315.","journal-title":"Circulation."},{"key":"1780_CR37","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1021\/bi052294c","volume":"45","author":"R Pejchal","year":"2006","unstructured":"Pejchal R, Campbell E, Guenther BD, Lennon BW, Matthews RG, Ludwig ML. Structural perturbations in the Ala \u2192 Val polymorphism of methylenetetrahydrofolate reductase: how binding of folates may protect against inactivation. Biochemistry. 2006;45:4808\u201318.","journal-title":"Biochemistry."},{"key":"1780_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.105.580332","volume":"113","author":"H McNulty","year":"2006","unstructured":"McNulty H, Dowey LRC, Strain JJ, Dunne A, Ward M, Molloy AM, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C\u2192T polymorphism. Circulation. 2006;113:74\u201380.","journal-title":"Circulation."},{"key":"1780_CR39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jama.291.5.565","volume":"291","author":"JF Toole","year":"2004","unstructured":"Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565\u201375.","journal-title":"JAMA."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01780-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-020-01780-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01780-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T02:02:32Z","timestamp":1605060152000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01780-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1780"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01780-x","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TUDA: Ethical approval was obtained from the Office for Research Ethics Committees Northern Ireland (reference number 08\/NIR03\/113), the Research Ethics Committee in St James\u2019s Hospital, and the Adelaide and Meath Hospital, Dublin. All participants provided written informed consent at the time of recruitment.NANS: The study was approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals, University College Cork, and the Human Ethics Research Committee of University College Dublin. All eligible and willing participants gave their written consent according to the Helsinki declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is a patent granted in Europe and pending elsewhere by Ward, McNulty, Strain, Horigan and Scott, on the use of riboflavin in the treatment of hypertension; the other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}